VE416 is a rationally defined bacterial consortium being developed for the treatment of allergic disease including peanut allergy. VE416 consists of clonal human commensal bacterial strains selected for their ability to suppress allergic responses and manufactured under GMP conditions. Wayne Shreffler, M.D., Ph.D., chief of pediatric allergy and immunology and director of the Food Allergy Center at Massachusetts General Hospital, has initiated a clinical investigator-sponsored trial in patients with peanut allergy to evaluate VE416 as a monotherapy, and in combination with oral immunotherapy (NCT03936998).